LAURA CHAMPAGNE: Open Payments
NPI 1992758684 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,994 in 99 payments from 14 companies in 2025. Trend: 2023 $3,147 · 2024 $1,680 · 2025 $1,994
Food & beverage: $1,994
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $474 |
| E.R. Squibb & Sons, L.L.C. | 14 | $322 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $233 |
| Neurocrine BioSciences, Inc. | 9 | $186 |
| ABBVIE INC. | 9 | $174 |
| Axsome Therapeutics, Inc. | 9 | $137 |
| Janssen Pharmaceuticals, Inc | 5 | $123 |
| Teva Pharmaceuticals USA, Inc. | 4 | $103 |
| Lundbeck LLC | 4 | $71 |
| Alkermes, Inc. | 3 | $48 |
Products named: REXULTI, COBENFY, CAPLYTA, INGREZZA, VRAYLAR, Auvelity, SPRAVATO, ABILIFY ASIMTUFII.
Industry payments across TX — which companies pay providers there.
